Scilex Holding Company announced that it has signed an insurance coverage agreement for ELYXYB®? with a national PBM, for their Medicare population potentially expanding coverage of ELYXYB®?. The company believe ELYXYB®?

is the first and only ready to use oral solution designed to deliver fast and long-lasting migraine relief with the proven safety of COX-2 selectivity that is FDA-approved for the acute treatment of migraine, with or without aura, in adults. Clinicians in a recent market research study expressed their desire for fast and safe alternatives for two large pools of acute migraine patients - those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use. ELYXYB's product profile mapped with a high degree of certainty to these stated unmet needs.

In clinical studies, patients treated with ELYXYB®? demonstrated pain relief in as little as 15 minutes, and significant pain relief compared to placebo within 45 minutes in approximately 50% of patients.